Concerns Build Over Surgisphere’s COVID-19 Dataset

NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.

Written byCatherine Offord

| 5 min read

Save for Later

Listen with Speechify

0:00

5:00

ABOVE: © ISTOCK.COM, WHYFRAMESTUDIO

Update (June 3): The World Health Organization today announced that it would be resuming hydroxychloroquine testing in its Solidarity Trial, following widespread criticism of The Lancet paper and the dataset it was based on.

Scientists are questioning the validity of two influential studies of COVID-19 patients as concerns grow about the provenance of the dataset underpinning them. Despite assurances from Surgisphere Corporation, an Illinois-based company that owns the data, hundreds of researchers have now signed open letters to The Lancet and the New England Journal of Medicine (NEJM), voicing their concerns. Today, NEJM and The Lancet issued expressions of concern about the reliability of the papers’ conclusions.

“Recently, substantive concerns have been raised about the quality of the information in that database,” writes NEJM editor-in-chief Eric Rubin in the expression of concern. “We have asked the authors to provide evidence that the data are reliable. In ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Catherine Offord
After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.
View Full Profile